Going for the golden mean: Now is an exciting time to have a diverse biotech portfolio

Healthcare innovations worth taking a shot at

Daniel Koller of BB Biotech

Daniel Koller of BB Biotech

The general public's knowledge of biotech has increased and improved exponentially following the pandemic. That is perhaps one of the positives we can take from Covid-19: Pfizer, Moderna, BionTech and AstraZeneca are all now household names.

Just as the public's knowledge has improved, so too have investors woken up to the opportunities and possibilities investing in biotechnology could bring. Before Covid-19 put a petri-dish around the...

To continue reading this article...

Join Investment week

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now


Already an Investment Week


More on Alternatives